Parasitism

R21 anti-malaria vaccine is a game changer: scientist who helped design it reflects on 30 years of research, and what it promises

Retrieved on: 
Thursday, April 25, 2024

Until three years ago nobody had developed a vaccine against any parasitic disease. Now there are two against malaria: the RTS,S and the R21 vaccines. Adrian Hill, director of the Jenner Institute at the University of Oxford and chief investigator for the R21 vaccine, tells Nadine Dreyer why he thinks this is a great era for malaria control.What makes malaria such a difficult disease to beat?Our hominoid predecessors were being infected by malaria parasites tens of millions of years ago, so these parasites had a lot of practice at clever tricks to escape immune systems long before we came along.

Key Points: 


Until three years ago nobody had developed a vaccine against any parasitic disease. Now there are two against malaria: the RTS,S and the R21 vaccines. Adrian Hill, director of the Jenner Institute at the University of Oxford and chief investigator for the R21 vaccine, tells Nadine Dreyer why he thinks this is a great era for malaria control.

What makes malaria such a difficult disease to beat?

  • Our hominoid predecessors were being infected by malaria parasites tens of millions of years ago, so these parasites had a lot of practice at clever tricks to escape immune systems long before we came along.
  • Additionally, the malaria parasite goes through four life cycle stages.
  • Medical researchers have been trying to make malaria vaccines for over 100 years.

How does the R21/Matrix-M vaccine work?

  • An antigen is any substance that causes the body to make an immune response against that substance.
  • We targeted the sporozoites, which is the form that the mosquito inoculates into your skin.
  • Read more:
    Two new malaria vaccines are being rolled out across Africa: how they work and what they promise

A child dies every minute from malaria in Africa. Why are children more susceptible than adults?

  • The age you’re most likely to die of malaria in Africa is when you are one year old.
  • For the first six months you are protected largely by your mother’s immunity and the antibodies she transfers during pregnancy.
  • Without malaria, children would be healthier in general — the disease makes you susceptible to other infections.

What about the pace of vaccine rollouts?

  • We’ve been disappointed that it’s taken more than six months to roll out the R21 vaccine since it was approved in October last year.
  • Compare that to a COVID-19 vaccine from Oxford and AstraZeneca that was approved on New Year’s Eve 2020 and rolled out in several countries the very next week.

How big a role will vaccines have in the fight to eradicate malaria?

  • Nobody is quite sure how many of the older tools such as insecticides and bed nets we need to carry on with.
  • Anti-malaria medication only lasts for days and parasites are building up resistance against these drugs as well.
  • There are about 40 million children born every year in malaria areas in Africa who would benefit from a vaccine.
  • The Serum Institute of India, our manufacturing and commercial partner, can produce hundreds of millions of doses each year.


Adrian Hill receives funding from government and charitable funders of malaria vaccine development. He has received funding awarded to the University of Oxford from the Serum Institute of India to support clinical trials of the R21/Matrix-M vaccine. He may benefit for a share of any royalty stream to Oxford University from the vaccine.

Two new malaria vaccines are being rolled out across Africa: how they work and what they promise

Retrieved on: 
Tuesday, April 23, 2024

Malaria incidents are on the rise. There were 249 million cases of this parasitic disease in 2022, five million more than in 2021. Africa suffers more than any other region from malaria, with 94% of cases and 95% of deaths worldwide. This year two revolutionary malaria vaccines are being rolled out across the continent. Nadine Dreyer asks Jaishree Raman if 2024 will be the year the continent takes a significant leap towards beating the disease.The RTS,S malaria vaccineThe long-awaited vaccine was described as a breakthrough for science, child health and malaria control.

Key Points: 


Malaria incidents are on the rise. There were 249 million cases of this parasitic disease in 2022, five million more than in 2021. Africa suffers more than any other region from malaria, with 94% of cases and 95% of deaths worldwide. This year two revolutionary malaria vaccines are being rolled out across the continent. Nadine Dreyer asks Jaishree Raman if 2024 will be the year the continent takes a significant leap towards beating the disease.

The RTS,S malaria vaccine

  • The long-awaited vaccine was described as a breakthrough for science, child health and malaria control.
  • It is being aimed at children under the age of 5, who make up about 80% of all malaria deaths in Africa.
  • Among children aged 5 and 17 months who received 4 doses of RTS,S, the vaccine prevented about 30% of them from developing severe malaria.
  • Since 2019 more than 2 million children in Ghana, Kenya and Malawi have been vaccinated with the RTS,S malaria vaccine.

R21/Matrix M

  • The R21 vaccine is a significant improvement on the RTS,S vaccine, with 75% efficacy over a year.
  • The R21/Matrix M vaccine is very cost-effective, projected to retail at $2-$4 a dose, comparable in price to other childhood vaccines used in Africa.
  • These very encouraging findings prompted several malaria-endemic African countries, including Ghana and Nigeria, to approve use of the R21/Matrix M vaccine well before the World Health Organization.
  • The WHO finally approved and prequalified R21/Matrix M for use in the last quarter of 2023.

No silver bullet

  • While the fight against malaria has been significantly bolstered by the availability of these vaccines, they are not the silver bullets that are going to get us to an Africa free of malaria.
  • This will be the year that many vulnerable young African children will have access to not one, but two malaria vaccines.


Jaishree Raman receives funding from the Global Fund, the Gates Foundation, the South Africa Research Trust, the South African Medical Research Council, the National Research Foundation, and the National Institute for Communicable Diseases. She is affiliated with the Wits Research Institute for Malaria, University of Witwatersrand, and the Institute for Sustainable Malaria Control, the University of Pretoria.

Shield Your Herd: University Products Leads the Charge with Premier Bovine Anaplasmosis Vaccine

Retrieved on: 
Tuesday, April 9, 2024

Rising Threat: Anaplasmosis Expands Across the U.S.

Key Points: 
  • Rising Threat: Anaplasmosis Expands Across the U.S.
    Anaplasmosis in cattle is primarily spread from the bites of infected ticks and horseflies.
  • "And despite widespread industry use, antibiotics were never meant to be a routine preventative cure," said Gene Luther from University Products.
  • And University Products' Anaplasmosis vaccine remains the optimal choice.
  • For more information on vaccine availability for ranchers and veterinarians, please contact University Products directly.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Pet flea and tick treatments contain pesticides that end up washing into the environment - here’s how

Retrieved on: 
Tuesday, April 9, 2024

However, these treatments are polluting our rivers and could pose a health risk to pet-loving families, according to new research.

Key Points: 
  • However, these treatments are polluting our rivers and could pose a health risk to pet-loving families, according to new research.
  • They spread over the skin of the animal making it toxic to fleas (and sometimes ticks) for at least one month.
  • They’re often sold as part of a pet healthcare plan, whereby pet owners make a monthly payment for a package of year-round treatments.
  • There were multiple likely additional pathways for these chemicals to end up going down the drain.
  • In my opinion, preventative flea treatment is neither necessary nor desirable in most cases.
  • Non-chemical methods such as flea traps, regular hot washing of the animal’s bedding to kill larval fleas and hoovering are effective.
  • There are also oral flea and tick treatments such as isoxazolines, which rapidly resolve flea infestations.

Proceed with precaution

  • To make sure newer classes of parasiticide such as isoxazolines remain as effective as possible, extensive preventative use cannot continue.
  • Previous research has also raised concerns about possible health risks to pet owners and veterinary professionals from chronic exposure to pet parasiticides.
  • Our work supports these concerns, demonstrating that fipronil and imidacloprid readily transfer to bedding and owner’s hands, so they will quickly get smeared around the household.


Dave Goulson receives funding from the Veterinary Medicines Directorate. He is a member of the Green Party.

Merck Continues the Fight against Schistosomiasis in a Storytelling Lab

Retrieved on: 
Tuesday, April 2, 2024

Merck, a leading science and technology company, announced the winners of its 2024 Bilharzia Storytelling Lab in Ethiopia.

Key Points: 
  • Merck, a leading science and technology company, announced the winners of its 2024 Bilharzia Storytelling Lab in Ethiopia.
  • This innovative initiative aims to develop creative solutions in order to raise awareness about schistosomiasis and, in doing so, bring about behavioral change.
  • View the full release here: https://www.businesswire.com/news/home/20240402803315/en/
    The winners of this year's Merck Bilharzia Storytelling Lab in Ethiopia (Photo: Business Wire)
    Schistosomiasis is one of the most prevalent parasitic diseases and affects more than 240 million people worldwide.
  • Read more about how Merck is committed to eliminating schistosomiasis: www.merckgroup.com/schistosomiasis
    View source version on businesswire.com: https://www.businesswire.com/news/home/20240402803315/en/

New pet owner survey suggests common myths fueling significant gap in prevention of deadly parasite for U.S. dogs and cats

Retrieved on: 
Tuesday, April 2, 2024

VANCOUVER, Wash., April 2, 2024 /PRNewswire/ -- Banfield Pet Hospital – the nation's leading provider of preventive veterinary care and part of the Mars Veterinary Health family of practices – surveyed 1,000 U.S. dog and cat owners and analyzed its pet medical record database to gain insights on the state of heartworm prevalence in pets, including seasonal and local trends.  

Key Points: 
  • According to the American Heartworm Society , more than a million pets in the U.S. have heartworm – a serious and potentially fatal parasite for dogs and cats that is contracted from mosquitos – and cases are on the rise.
  • Despite the growing prevalence, new survey findings from Banfield reveal nearly 40% of dog and cat owners don't believe their pet is at risk of getting heartworms and nearly 30% said their pet is not on heartworm prevention.
  • Further, 21% of pet owners don't believe the mosquitos in their state carry the parasite, despite heartworm cases being diagnosed in all 50 states.
  • Notably, states including Washington and Oregon made the top 10 list, which according to the American Heartworm Society are areas with historically low heartworm rates.

Nonprofit Companion Animal Parasite Council (CAPC) Warns Parasitic Pet Diseases Will Spread Further in 2024

Retrieved on: 
Tuesday, April 2, 2024

SALEM, Ore., April 2, 2024 /PRNewswire-PRWeb/ -- The nonprofit Companion Animal Parasite Council (CAPC), the nation's leading authority on parasitic diseases that threaten the health of pets and people, today warned of the continued expansion of heartworm, Lyme Disease and other tick-borne diseases throughout the United States in 2024. Pet owners can learn more about higher-than-average parasitic disease risks CAPC predicts in its 2024 Pet Parasite Forecast released today, as well as in its corresponding monthly prevalence maps at petdiseasealerts.org.

Key Points: 
  • Pet owners can learn more about higher-than-average parasitic disease risks CAPC predicts in its 2024 Pet Parasite Forecast released today, as well as in its corresponding monthly prevalence maps at petdiseasealerts.org .
  • While CAPC's nationwide annual forecasts track progression of diseases, our monthly forecasts at petdiseasealerts.org help pet owners understand immediate threats in their neighborhoods.
  • In its 2024 Pet Parasite Forecast , CAPC reports ticks and mosquitoes remain the principal transmitters of pet and human vector-borne diseases.
  • Both the annual forecast and the 30-Day Pet Parasite Forecast Maps are designed to alert pet owners of impending outbreaks.

1.9 Million Doses of NexGard® PLUS (afoxolaner, moxidectin and pyrantel chewable tablets): Donated by Boehringer Ingelheim Cares Foundation to Aid Shelter Dogs in Need

Retrieved on: 
Friday, March 15, 2024

The Boehringer Ingelheim Cares Foundation has donated 1.9 million doses of NexGard® PLUS to animal shelters in need.

Key Points: 
  • The Boehringer Ingelheim Cares Foundation has donated 1.9 million doses of NexGard® PLUS to animal shelters in need.
  • The Foundation has donated 1.9 million doses of NexGard® PLUS chews, a delicious beef-flavored soft chew, designed to protect dogs from fleas and ticks, prevent heartworm disease, and treat and control roundworms and hookworms.
  • Over 6 million doses of NexGard® PLUS chews have been sold since its launch in 2023.
  • NexGard® PLUS (afoxolaner, moxidectin, and pyrantel chewable tablets) are for use in dogs only.